Publications are yet another way to show our commitment to delivering high quality research and to show the impact of our work. This also gives participants and the public access to the results of trials that they have participated in.
Publications
Publications
We endeavour to make science accessible
June 2024
An u A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti‐Wolbachia Candidate Macrofilaricide – Devereux – Clinical Pharmacology in Drug Development – Wiley Online Library
April 2023
An update on the COV-Boost study: where results relating to vaccines available to the UK to use in booster programmes have been shared with the JCVI and Department of Health “in real time”.
The full results from blood tests taken 8 months following the 3rd dose vaccines have just been published in the Journal of Infection.
April 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial:
May 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial:
April 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial:
Dec 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial:
October 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2:
September 2021
Human Mass Balance and Metabolite Profiling of [ 14 C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer:
August 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study:
April 2021
Detection of SARS-CoV-2 infection by saliva and nasopharyngeal sampling in frontline healthcare workers: an observational cohort study:
Become a Volunteer
Register to Take Part
Register your interest in becoming a potential volunteer for clinical trials at the CRU or find more information about consenting for registration with us.
© 2023 NIHR Liverpool Clinical Research Facility